Your data on MRCVSonline
The nature of the services provided by Vision Media means that we might obtain certain information about you.
Please read our Data Protection and Privacy Policy for details.

In addition, (with your consent) some parts of our website may store a 'cookie' in your browser for the purposes of
functionality or performance monitoring.
Click here to manage your settings.
If you would like to forward this story on to a friend, simply fill in the form below and click send.

Your friend's email:
Your email:
Your name:
 
 
Send Cancel

Scientists ID drug dosage for fungal disease
Aspergillosis is a respiratory fungal disease commonly seen in African penguins under managed care.
Treatment previously caused adverse effects in penguins
 
Liverpool researchers have found the most effective drug dosage to help penguins fight off a common disease.

Aspergillosis is a respiratory fungal disease commonly seen in African penguins under managed care. The anti-fungal medication itraconazole, which was previously used to treat the disease, failed due to drug resistance.

Another anti-fungal called voriconazole has been used recently, but the dosing was based on other avian medications and penguins suffered adverse effects as a result.

Researchers from the University of Liverpool wanted to identify the most effective dose of the drug. Led by Dr Katharine Stott, the team analysed the concentration of voriconazole in plasma taken from African penguins, in order to determine the effectiveness of multiple single and daily oral doses.

This data was used to construct a mathematical model to simulate alternative dosing strategies to find one that replicated the drug exposure that is effective in humans, whilst avoiding toxicity.

The findings, which were published in BioOne, show that 5mg/kg of voriconazole once a day is a safe and effective dosing strategy for African penguins with invasive aspergillosis.

Become a member or log in to add this story to your CPD history

Annual submission deadline small pet animal exemptions

News Story 1
 Companies marketing medicines for small pets exempt from authorisation must submit their annual return to the Veterinary Medicines Directorate (VMD) by 30 November 2026.

Submitting this annual return ensures continued compliance with regulatory requirements for products marketed without a full Marketing Authorisation. The exemption specifically applies to products intended for animals, cage birds, terrarium animals, small rodents, ferrets and rabbits.

For further details and submission guidelines, visit the gov.uk website.  

Click here for more...
News Shorts
BVA urges 'continued vigilance' over bluetongue

The British Veterinary Association (BVA) has urged vigilance following a concerning rise in Bluetongue (BTV) cases in sheep and cattle.

In a recent statement, the BVA noted that members are reporting more severe clinical signs and higher mortality rates than in previous years.

'We know that farm vets are working hard to support farmers and animals affected by this outbreak, during what is an extremely difficult time for all involved,' they stated. 'Continued vigilance to identify disease early is vital and vaccination remains the best way of protecting animals from this disease.'